Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$0.97
+$0.0512 · +5.57%
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Latest quote
$0.97
+$0.0512 · +5.57%
After-hours
$0.9903
+$0.0203 · +2.09%
Oct 9, 4:15 PM ET
Regular session · ET · Market data may be delayed.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Day range
Current $0.97
52-week range
Current $0.97
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
70
Undervalued
Sentiment
52
Mixed
Risk
49
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Day range
Current $0.97
52-week range
Current $0.97
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 41.71M USD | 37.3M USD | 34.07M USD | 28.67M USD | 24.1M USD |
| Cost of goods sold | 8.9M USD | 18.61M USD | 17.44M USD | 15.19M USD | 12.74M USD |
| Gross profit | 32.8M USD | 18.7M USD | 16.63M USD | 13.49M USD | 11.36M USD |
| Research and development | 3.72M USD | 2.09M USD | 77K USD | — | — |
| Selling, general, and administrative | 38.13M USD | 33.84M USD | 39.13M USD | 35.87M USD | 37.21M USD |
| Operating expenses | 41.95M USD | 35.92M USD | 39.3M USD | 32.07M USD | 36.56M USD |
| Interest income | — | 30K USD | 132K USD | 175K USD | 16K USD |
| Interest expense | 452K USD | 2.11M USD | 600K USD | 370K USD | 360K USD |
| Depreciation and amortization | 868K USD | 1.15M USD | 1.06M USD | 1.17M USD | 540K USD |
| Operating income | −9.15M USD | −17.21M USD | −22.68M USD | −18.58M USD | −25.2M USD |
| Net income | −10.54M USD | −17.76M USD | −20.13M USD | −640K USD | −37.71M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 5, 2023 | 1:20 | — | — |
Stock split | Feb 7, 2023 | 209:200 | — | — |
Stock split | Jun 23, 2021 | 1,027:1,000 | — | — |
Stock split | Feb 8, 2018 | 1,049:1,000 | — | — |
Effective Jul 5, 2023
1:20
Effective Feb 7, 2023
209:200
Effective Jun 23, 2021
1,027:1,000
Effective Feb 8, 2018
1,049:1,000
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
